SCHEMBL3765301

SCHEMBL3765301

CC1(C)OB(c2ccc3nc(-c4ccccc4)[nH]c3c2)OC1(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.52
RAB9A P51151 5/20 0.52
KDM4E B2RXH2 4/20 0.52
ALDH1A1 P00352 4/20 0.52
HPGD P15428 4/20 0.52
MAPT P10636 4/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
TP53 P04637 3/20 0.52
HSD17B10 Q99714 3/20 0.52
GAA P10253 2/20 0.52
GLA P06280 1/20 0.52
HTT P42858 1/20 0.52
GFER P55789 1/20 0.52
RCE1 Q9Y256 1/20 0.52
MEN1 O00255 1/20 0.52
CYP3A4 P08684 1/20 0.52
MAPK1 P28482 1/20 0.52
KMT2A Q03164 1/20 0.52
FTO Q9C0B1 1/20 0.52
TSHR P16473 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16062202 0.90 LPL (0.51) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL481643 0.84 NPC1 (0.55) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL29653942 0.83 KDM4E (0.53) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL15574354 0.79 ALDH1A1 (0.49) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL3761817 0.79 GAA (0.55) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL3759602 0.79 RIPK1 (0.53) NPC1RAB9AMAPTSMN1; SMN2HTT
SCHEMBL15296449 0.78 EGFR (0.40) ALDH1A1HPGDSMN1; SMN2LPLLIPG
SCHEMBL3831957 0.78 PLAU (0.47) ALDH1A1MEN1KMT2ALPLLIPG
SCHEMBL15596487 0.77 LIPG (0.55) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL31282208 0.77 LIPG (0.55) NPC1RAB9AKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365566-B2 Cinnoline derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-14 US disclosed
US-9365566-B2 Cinnoline derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-14 US disclosed
US-20150038510-A1 CINNOLINE DERIVATIVES TAKEDA CALIFORNIA, INC. 2015-02-05 US disclosed
US-20150038510-A1 CINNOLINE DERIVATIVES TAKEDA CALIFORNIA, INC. 2015-02-05 US disclosed
EP-2435435-B1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBVIE INC (US) 2014-01-29 EP disclosed
WO-2013148603-A1 CINNOLINE DERIVATIVES AS AS BTK INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-10-03 WO disclosed
WO-2013148603-A1 CINNOLINE DERIVATIVES AS AS BTK INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-10-03 WO disclosed
US-8536180-B2 Pyrimidine inhibitors of kinase activity ABBVIE INC. (US) 2013-09-17 US disclosed
WO-2010138575-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 WO disclosed
US-20100305118-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305118-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY IGF1R, TK1, CDK2 NPC1 3296/4885RAB9A 3286/4885KDM4E 3417/4885
US-20150038510-A1 CINNOLINE DERIVATIVES BTK, LYN, ABL1 NPC1 1588/4885RAB9A 1218/4885KDM4E 3377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.